The antibody-mediated rejection market is expanding as the number of organ transplants rises and awareness of AMR’s impact on graft survival grows. Advances in diagnostic assays, biomarker-driven monitoring, and targeted therapies, including Felzartamab (Biogen), Imlifidase (Hansa…
